Berberis aristata/Silybum marianum fixed combination (Berberol(®)) effects on lipid profile in dyslipidemic patients intolerant to statins at high dosages: a randomized, placebo-controlled, clinical trial

Phytomedicine : International Journal of Phytotherapy and Phytopharmacology
G DerosaPamela Maffioli

Abstract

to evaluate the efficacy of Berberis aristata/Silybum marianum (Berberol(®)) in a sample of dyslipidemic patients intolerant to statins at high dosages in a randomized, double blind, placebo-controlled clinical trial. we enrolled 175 euglycemic, dyslipidemic subjects, intolerant to statins at high dosages. During the run-in period, statins were stopped for 1 month, then they were re-introduced at the half of the previously taken dose. After that, patients were randomized to placebo or Berberol(®), 1 tablet during the lunch and 1 tablet during the dinner, for 6 months. Anthropometric, metabolic and inflammatory parameters were assessed at randomization, at 3 and 6 months. fasting plasma glucose, insulin, and HOMA-index levels were reduced by Berberol(®), but not by placebo; moreover they were lower than the ones recorded with placebo. Total cholesterol, LDL-C, triglycerides, and myeloperoxidase did not change after 6 months since the reduction of statin dosage and the introduction of Berberol(®), while they increased in the placebo group, and were higher compared to the ones obtained with active treatment. No patients had serious adverse events in both groups. our study displays the rationale of the combination of Berberol(®) an...Continue Reading

References

Oct 8, 1999·Diabetic Medicine : a Journal of the British Diabetic Association
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Dec 7, 2002·The American Journal of Cardiology·Alan S Brown
Dec 7, 2002·The American Journal of Cardiology·Michael H Davidson
Sep 1, 1955·The Journal of Clinical Investigation·R J HAVELJ H BRAGDON
Apr 10, 2004·Drug Metabolism Reviews·Shufeng ZhouBalram Chowbay
Apr 21, 2004·Annals of Internal Medicine·Sandeep VijanUNKNOWN American College of Physicians
May 27, 2004·Diabetes Care·Tara M WallaceDavid R Matthews
Aug 17, 2004·European Journal of Nutrition·Arrigo F G CiceroAntonio Gaddi
Nov 9, 2005·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Lucie SobolováKarel Urbánek
Jul 22, 2008·Metabolism: Clinical and Experimental·Wei-Jia KongJian-Dong Jiang
Mar 27, 2010·Journal of the American College of Cardiology·Pradeep NatarajanChristopher P Cannon
Feb 1, 2011·Journal of Pharmaceutical and Biomedical Analysis·Jianbo ChenJong Seong Kang
Jul 12, 2012·Expert Opinion on Biological Therapy·Giuseppe DerosaArrigo F G Cicero
Jul 14, 2012·Expert Opinion on Drug Safety·Arrigo F G CiceroSibel Ertek
Feb 28, 2013·Expert Opinion on Biological Therapy·Giuseppe DerosaPamela Maffioli
Aug 27, 2013·Expert Opinion on Biological Therapy·Giuseppe DerosaPamela Maffioli

❮ Previous
Next ❯

Citations

Mar 7, 2020·Journal of Basic and Clinical Physiology and Pharmacology·Fernanda Caetano Camini, Daniela Caldeira Costa
Mar 7, 2020·Frontiers in Pharmacology·Tarun BelwalJavier Echeverría
Jan 15, 2019·Phytotherapy Research : PTR·Mohsen Imenshahidi, Hossein Hosseinzadeh
Oct 13, 2020·Archives of Physiology and Biochemistry·Babak RoshanravanSaeed Samarghandian
Sep 21, 2020·Annals of Hepatology·Karla MacDonald-RamosMarco Cerbón
Sep 3, 2020·Journal of Ethnopharmacology·Ilias MarmouziMourad Kharbach
Jul 16, 2021·Frontiers in Immunology·Giuseppe DerosaFrancesco Di Pierro
Mar 10, 2020·Complementary Therapies in Medicine·Mohammad Reza AminiSakineh Shab-Bidar

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.